Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt 1.31
VAR's Cash to Debt is ranked lower than
61% of the 316 Companies
in the Global Medical Devices industry.

( Industry Median: 2.30 vs. VAR: 1.31 )
Ranked among companies with meaningful Cash to Debt only.
VAR' s Cash to Debt Range Over the Past 10 Years
Min: 0.27  Med: 3.20 Max: 15.02
Current: 1.31
0.27
15.02
Equity to Asset 0.44
VAR's Equity to Asset is ranked lower than
77% of the 295 Companies
in the Global Medical Devices industry.

( Industry Median: 0.65 vs. VAR: 0.44 )
Ranked among companies with meaningful Equity to Asset only.
VAR' s Equity to Asset Range Over the Past 10 Years
Min: 0.34  Med: 0.50 Max: 0.57
Current: 0.44
0.34
0.57
Interest Coverage 66.03
VAR's Interest Coverage is ranked lower than
57% of the 162 Companies
in the Global Medical Devices industry.

( Industry Median: 481.81 vs. VAR: 66.03 )
Ranked among companies with meaningful Interest Coverage only.
VAR' s Interest Coverage Range Over the Past 10 Years
Min: 66.56  Med: 100.85 Max: 226.41
Current: 66.03
66.56
226.41
F-Score: 7
Z-Score: 4.49
M-Score: -2.39
WACC vs ROIC
6.29%
31.54%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 17.19
VAR's Operating margin (%) is ranked higher than
85% of the 302 Companies
in the Global Medical Devices industry.

( Industry Median: 1.89 vs. VAR: 17.19 )
Ranked among companies with meaningful Operating margin (%) only.
VAR' s Operating margin (%) Range Over the Past 10 Years
Min: 17.71  Med: 20.48 Max: 22.67
Current: 17.19
17.71
22.67
Net-margin (%) 13.06
VAR's Net-margin (%) is ranked higher than
83% of the 302 Companies
in the Global Medical Devices industry.

( Industry Median: 0.95 vs. VAR: 13.06 )
Ranked among companies with meaningful Net-margin (%) only.
VAR' s Net-margin (%) Range Over the Past 10 Years
Min: 13.24  Med: 14.65 Max: 15.36
Current: 13.06
13.24
15.36
ROE (%) 24.36
VAR's ROE (%) is ranked higher than
95% of the 286 Companies
in the Global Medical Devices industry.

( Industry Median: 2.05 vs. VAR: 24.36 )
Ranked among companies with meaningful ROE (%) only.
VAR' s ROE (%) Range Over the Past 10 Years
Min: 24.24  Med: 28.73 Max: 33.66
Current: 24.36
24.24
33.66
ROA (%) 11.49
VAR's ROA (%) is ranked higher than
88% of the 317 Companies
in the Global Medical Devices industry.

( Industry Median: -0.07 vs. VAR: 11.49 )
Ranked among companies with meaningful ROA (%) only.
VAR' s ROA (%) Range Over the Past 10 Years
Min: 11.83  Med: 15.13 Max: 17.33
Current: 11.49
11.83
17.33
ROC (Joel Greenblatt) (%) 65.67
VAR's ROC (Joel Greenblatt) (%) is ranked higher than
92% of the 314 Companies
in the Global Medical Devices industry.

( Industry Median: 3.57 vs. VAR: 65.67 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
VAR' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 70.35  Med: 96.68 Max: 130.37
Current: 65.67
70.35
130.37
Revenue Growth (3Y)(%) 7.60
VAR's Revenue Growth (3Y)(%) is ranked higher than
66% of the 209 Companies
in the Global Medical Devices industry.

( Industry Median: 3.60 vs. VAR: 7.60 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
VAR' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -27.1  Med: 11.80 Max: 17.4
Current: 7.6
-27.1
17.4
EBITDA Growth (3Y)(%) 2.60
VAR's EBITDA Growth (3Y)(%) is ranked higher than
50% of the 183 Companies
in the Global Medical Devices industry.

( Industry Median: 2.60 vs. VAR: 2.60 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
VAR' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -47.7  Med: 13.90 Max: 65.8
Current: 2.6
-47.7
65.8
EPS Growth (3Y)(%) 2.80
VAR's EPS Growth (3Y)(%) is ranked higher than
50% of the 187 Companies
in the Global Medical Devices industry.

( Industry Median: 2.90 vs. VAR: 2.80 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
VAR' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -58.5  Med: 15.50 Max: 113.8
Current: 2.8
-58.5
113.8
» VAR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

VAR Guru Trades in Q1 2015

Paul Tudor Jones 2,700 sh (+3.85%)
CI Can Am Small Cap 58,925 sh (unchged)
John Hussman 125,000 sh (unchged)
Westport Asset Management 277,500 sh (unchged)
First Pacific Advisors 124,700 sh (-2.27%)
Jeremy Grantham 225,824 sh (-8.55%)
Charles Brandes 133,327 sh (-11.96%)
David Rolfe 2,147,870 sh (-32.59%)
Ray Dalio 9,961 sh (-50.19%)
Joel Greenblatt 100,133 sh (-57.64%)
Jim Simons 98,300 sh (-62.84%)
» More
Q2 2015

VAR Guru Trades in Q2 2015

Ray Dalio 129,674 sh (+1201.82%)
Paul Tudor Jones 11,796 sh (+336.89%)
John Hussman 150,000 sh (+20.00%)
David Rolfe 2,307,861 sh (+7.45%)
First Pacific Advisors 124,700 sh (unchged)
Westport Asset Management 277,500 sh (unchged)
Jim Simons Sold Out
Charles Brandes 132,527 sh (-0.60%)
Jeremy Grantham 185,124 sh (-18.02%)
Joel Greenblatt 8,407 sh (-91.60%)
» More
Q3 2015

VAR Guru Trades in Q3 2015

Jim Simons 284,800 sh (New)
First Eagle Investment 153,130 sh (New)
Joel Greenblatt 500,631 sh (+5854.93%)
Paul Tudor Jones 21,756 sh (+84.44%)
Charles Brandes 135,215 sh (+2.03%)
CI Can Am Small Cap 58,925 sh (unchged)
Westport Asset Management 277,500 sh (unchged)
Ray Dalio Sold Out
David Rolfe 1,945,422 sh (-15.70%)
First Pacific Advisors 84,400 sh (-32.32%)
John Hussman 50,000 sh (-66.67%)
Jeremy Grantham 18,616 sh (-89.94%)
» More
Q4 2015

VAR Guru Trades in Q4 2015

Ray Dalio 49,756 sh (New)
Charles Brandes 181,830 sh (+34.47%)
Westport Asset Management 277,500 sh (unchged)
John Hussman Sold Out
Jim Simons 195,200 sh (-31.46%)
» More
» Details

Insider Trades

Latest Guru Trades with VAR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Varian Medical Systems Inc

Wedgewood Partners Comments on Varian Medical Systems - Jan 18, 2016

We sold Varian Medical Systems (NYSE:VAR) early in the quarter. The Company maintains its position as the dominant supplier of radiotherapy equipment and software, worldwide. We see Varian’s core business growing earnings per share at a steady, low to mid-single digit rate, as developed markets have reached maturity. In addition, the dramatic devaluation of the Japanese yen relative to the U.S. Dollar has caused some competitive pressures in its non-core Imaging and Components segment, further pressuring growth. While Imaging Components might regain competitiveness over the next few years, we do not think it will be enough to drive earnings growth to our required rate.



From Wedgewood Partners' fourth quarter 2015 client letter.



Check out David Rolfe latest stock trades

David Rolfe Comments on Varian Medical Systems - Apr 18, 2014

Varian Medical Systems (VAR) has been a staple in our portfolio since the fall of 2005. The stock has rebounded smartly, up +31% from its April 2013 lows through the first quarter. Varian continues to be the global market share and technological leader in the radiation oncology business. Unfortunately, the incidence of cancer continues its deadly growth. In the U.S. alone, the American Cancer Society projects that some 1.7 million people will be diagnosed with cancer. Expectations of new cancer cases around the world are approaching 25 million over the next three decades. Of these new cases, approximately two-­‐thirds will be treated with some sort of radiation therapy. Varian has been at the forefront of linear particle accelerator since the late 1940's. Today the Company's installed base numbers over 7,300 LINACS across the globe – a 60% market share. As impressive as that may sound, the availability of state-­‐of-­‐the-­‐art radiation therapy (radiosurgery and proton therapy) outside of the U.S. is woefully low. The developed world has access to 35 to 110 LINACS per million people over the age of 65. In the U.S., it's 110 LINACS per million. Western Europe and Japan is 35 to 65 per million. In India, Africa, Eastern Europe and Southeast Asia there are between 1 and 20 machines per million. In China there is less than 10 machines per million. Complementing the Company's long-­‐term growth opportunity in radiation therapy is the secular trend in the "digitization of radiology," which is a key driver of their lucrative software and flat-­‐panel services business, plus their X-­‐ray tube replacement business that sells into the installed base of competing LINACS. The Company's initiatives to drive greater productivity continue to bear fruit. In 2013 sales per employee increased 14% and operating income per employee increased 20% over 2012 levels. Such productivity has helped the Company offset the continuing losses as they rollout their proton therapy machines. Cutting edge technologies such as proton therapy are one of the many reasons why cancer survivorship rates are up to nearly 70% from 50% from just the 1970's. You will be hearing much more about the marvels of proton therapy in the years to come. The key benefit of proton therapy over the latest x-­‐ray technology is that proton beams, due to proton's relatively larger sub-­‐atomic mass, can be controlled and stopped at the tumor. Conventional X-­‐rays particles cannot be 3 stopped and risk damaging surrounding healthy cells. Due to the exceptional accuracy of a proton beam, the oncologist can more safely deliver much higher doses of radiation (hypofraction), which kills cancer faster with fewer treatments. Furthermore, tumors that are close to vital organs are ideal for proton therapy. These include head and neck, breast, lung, gastrointestinal, prostate and spine. Proton therapy is also ideal for children to avoid longer-­‐term side effects of traditional radiation therapy. The advantages of this therapy have been known since the 1940's, but the cost of commercialization has been a nearly insurmountable hurdle. The Varian proton therapy equipped facility at the Scripps Proton Therapy center in San Diego just went online in January. This $220 million, 102,000 square-­‐foot, facility is only the 15th proton therapy facility in the U.S. At its core sits a 95-­‐ton superconducting cyclotron where the proton beam is generated using oxygen and hydrogen to create a plasma stream. Protons are then extracted and accelerated to roughly 100,000 miles per second. Such miracles of science and technology (Cincinnati Children's Hospital just recently placed a proton order) come at considerable costs. The Company needs to get the costs of such systems below $25 million in order to drive any meaningful growth and profitability from proton therapy. Given Varian's long and exceptional history of innovation with LINACS, combined with proton therapy's high barriers to entry, we believe the Company is well-­‐positioned to eventually reap a substantial proportion of any potential financial rewards generated by this ground-­‐breaking technology. Stericycle continued its steady streak of growth. Last quarter earnings per share were up 12%, driven by a 13% increase in revenues, compared to the December 2012 calendar quarter. Stericycle is able to methodically deliver such growth through a unique combination of organic and inorganic means. For instance, during the quarter they closed eight acquisitions that will generate roughly $34 million in incremental annual revenues. As for the Company's competitive positioning, the regulated medical waste industry market opportunity is roughly $10.5 billion spread across a highly fragmented competitive field, consisting of regional or local players, with none generating revenues above $100 million.

From David Rolfe (Trades, Portfolio)'s Wedgewood Partners first quarter 2014 commentary.

Check out David Rolfe latest stock trades

Top Ranked Articles about Varian Medical Systems Inc

Wedgewood Partners Comments on Varian Medical Systems Guru stock highlight
We sold Varian Medical Systems (NYSE:VAR) early in the quarter. The Company maintains its position as the dominant supplier of radiotherapy equipment and software, worldwide. We see Varian’s core business growing earnings per share at a steady, low to mid-single digit rate, as developed markets have reached maturity. In addition, the dramatic devaluation of the Japanese yen relative to the U.S. Dollar has caused some competitive pressures in its non-core Imaging and Components segment, further pressuring growth. While Imaging Components might regain competitiveness over the next few years, we do not think it will be enough to drive earnings growth to our required rate. Read more...
David Rolfe Trims Holdings in Alphabet, Visa in 3rd Quarter A look at Wedgewood Partners' largest sales
Wedgewood Partners Inc. was founded in 1988 with the goal of providing investors with a superior approach to managing investment portfolios. David Rolfe (Trades, Portfolio) has been Wedgewood's CIO for 18 years. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 18.40
VAR's P/E(ttm) is ranked higher than
71% of the 257 Companies
in the Global Medical Devices industry.

( Industry Median: 26.20 vs. VAR: 18.40 )
Ranked among companies with meaningful P/E(ttm) only.
VAR' s P/E(ttm) Range Over the Past 10 Years
Min: 12.16  Med: 20.94 Max: 40.86
Current: 18.4
12.16
40.86
Forward P/E 15.31
VAR's Forward P/E is ranked higher than
68% of the 186 Companies
in the Global Medical Devices industry.

( Industry Median: 17.83 vs. VAR: 15.31 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 18.30
VAR's PE(NRI) is ranked higher than
70% of the 193 Companies
in the Global Medical Devices industry.

( Industry Median: 27.30 vs. VAR: 18.30 )
Ranked among companies with meaningful PE(NRI) only.
VAR' s PE(NRI) Range Over the Past 10 Years
Min: 11.14  Med: 20.84 Max: 40.86
Current: 18.3
11.14
40.86
P/B 4.48
VAR's P/B is ranked lower than
83% of the 383 Companies
in the Global Medical Devices industry.

( Industry Median: 2.50 vs. VAR: 4.48 )
Ranked among companies with meaningful P/B only.
VAR' s P/B Range Over the Past 10 Years
Min: 3.06  Med: 5.25 Max: 11.36
Current: 4.48
3.06
11.36
P/S 2.40
VAR's P/S is ranked lower than
54% of the 381 Companies
in the Global Medical Devices industry.

( Industry Median: 2.22 vs. VAR: 2.40 )
Ranked among companies with meaningful P/S only.
VAR' s P/S Range Over the Past 10 Years
Min: 1.62  Med: 2.98 Max: 5.98
Current: 2.4
1.62
5.98
PFCF 20.05
VAR's PFCF is ranked higher than
78% of the 204 Companies
in the Global Medical Devices industry.

( Industry Median: 30.54 vs. VAR: 20.05 )
Ranked among companies with meaningful PFCF only.
VAR' s PFCF Range Over the Past 10 Years
Min: 14.57  Med: 22.43 Max: 47.82
Current: 20.05
14.57
47.82
POCF 16.10
VAR's POCF is ranked higher than
72% of the 273 Companies
in the Global Medical Devices industry.

( Industry Median: 19.47 vs. VAR: 16.10 )
Ranked among companies with meaningful POCF only.
VAR' s POCF Range Over the Past 10 Years
Min: 11.51  Med: 18.13 Max: 37.85
Current: 16.1
11.51
37.85
EV-to-EBIT 12.36
VAR's EV-to-EBIT is ranked higher than
77% of the 266 Companies
in the Global Medical Devices industry.

( Industry Median: 23.19 vs. VAR: 12.36 )
Ranked among companies with meaningful EV-to-EBIT only.
VAR' s EV-to-EBIT Range Over the Past 10 Years
Min: 6.8  Med: 13.60 Max: 25.8
Current: 12.36
6.8
25.8
EV-to-EBITDA 11.02
VAR's EV-to-EBITDA is ranked higher than
72% of the 292 Companies
in the Global Medical Devices industry.

( Industry Median: 16.58 vs. VAR: 11.02 )
Ranked among companies with meaningful EV-to-EBITDA only.
VAR' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.3  Med: 12.40 Max: 23.6
Current: 11.02
6.3
23.6
PEG 3.39
VAR's PEG is ranked higher than
50% of the 68 Companies
in the Global Medical Devices industry.

( Industry Median: 3.39 vs. VAR: 3.39 )
Ranked among companies with meaningful PEG only.
VAR' s PEG Range Over the Past 10 Years
Min: 0.76  Med: 1.29 Max: 3.59
Current: 3.39
0.76
3.59
Shiller P/E 23.33
VAR's Shiller P/E is ranked higher than
78% of the 69 Companies
in the Global Medical Devices industry.

( Industry Median: 31.42 vs. VAR: 23.33 )
Ranked among companies with meaningful Shiller P/E only.
VAR' s Shiller P/E Range Over the Past 10 Years
Min: 21.83  Med: 28.75 Max: 45.02
Current: 23.33
21.83
45.02
Current Ratio 1.83
VAR's Current Ratio is ranked lower than
68% of the 316 Companies
in the Global Medical Devices industry.

( Industry Median: 2.66 vs. VAR: 1.83 )
Ranked among companies with meaningful Current Ratio only.
VAR' s Current Ratio Range Over the Past 10 Years
Min: 1.42  Med: 1.81 Max: 2.33
Current: 1.83
1.42
2.33
Quick Ratio 1.38
VAR's Quick Ratio is ranked lower than
66% of the 316 Companies
in the Global Medical Devices industry.

( Industry Median: 2.00 vs. VAR: 1.38 )
Ranked among companies with meaningful Quick Ratio only.
VAR' s Quick Ratio Range Over the Past 10 Years
Min: 1.13  Med: 1.45 Max: 1.87
Current: 1.38
1.13
1.87
Days Inventory 124.03
VAR's Days Inventory is ranked higher than
56% of the 281 Companies
in the Global Medical Devices industry.

( Industry Median: 142.23 vs. VAR: 124.03 )
Ranked among companies with meaningful Days Inventory only.
VAR' s Days Inventory Range Over the Past 10 Years
Min: 69.24  Med: 95.37 Max: 119.05
Current: 124.03
69.24
119.05
Days Sales Outstanding 89.96
VAR's Days Sales Outstanding is ranked lower than
65% of the 266 Companies
in the Global Medical Devices industry.

( Industry Median: 72.25 vs. VAR: 89.96 )
Ranked among companies with meaningful Days Sales Outstanding only.
VAR' s Days Sales Outstanding Range Over the Past 10 Years
Min: 85.76  Med: 90.38 Max: 107.78
Current: 89.96
85.76
107.78
Days Payable 34.27
VAR's Days Payable is ranked lower than
77% of the 256 Companies
in the Global Medical Devices industry.

( Industry Median: 59.85 vs. VAR: 34.27 )
Ranked among companies with meaningful Days Payable only.
VAR' s Days Payable Range Over the Past 10 Years
Min: 30.46  Med: 36.26 Max: 41.88
Current: 34.27
30.46
41.88

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 11.77
VAR's Price/Net Current Asset Value is ranked lower than
69% of the 296 Companies
in the Global Medical Devices industry.

( Industry Median: 6.13 vs. VAR: 11.77 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
VAR' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 2.73  Med: 11.59 Max: 23.78
Current: 11.77
2.73
23.78
Price/Tangible Book 5.41
VAR's Price/Tangible Book is ranked lower than
59% of the 377 Companies
in the Global Medical Devices industry.

( Industry Median: 4.13 vs. VAR: 5.41 )
Ranked among companies with meaningful Price/Tangible Book only.
VAR' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.88  Med: 5.61 Max: 10.25
Current: 5.41
0.88
10.25
Price/Projected FCF 1.19
VAR's Price/Projected FCF is ranked higher than
77% of the 211 Companies
in the Global Medical Devices industry.

( Industry Median: 1.86 vs. VAR: 1.19 )
Ranked among companies with meaningful Price/Projected FCF only.
VAR' s Price/Projected FCF Range Over the Past 10 Years
Min: 1.11  Med: 1.45 Max: 3.13
Current: 1.19
1.11
3.13
Price/DCF (Earnings Based) 1.16
VAR's Price/DCF (Earnings Based) is ranked higher than
80% of the 44 Companies
in the Global Medical Devices industry.

( Industry Median: 1.77 vs. VAR: 1.16 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 0.83
VAR's Price/Median PS Value is ranked higher than
65% of the 383 Companies
in the Global Medical Devices industry.

( Industry Median: 0.96 vs. VAR: 0.83 )
Ranked among companies with meaningful Price/Median PS Value only.
VAR' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.71  Med: 0.94 Max: 1.52
Current: 0.83
0.71
1.52
Price/Peter Lynch Fair Value 3.32
VAR's Price/Peter Lynch Fair Value is ranked lower than
66% of the 71 Companies
in the Global Medical Devices industry.

( Industry Median: 2.41 vs. VAR: 3.32 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
VAR' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.92  Med: 1.28 Max: 3.26
Current: 3.32
0.92
3.26
Price/Graham Number 2.12
VAR's Price/Graham Number is ranked higher than
55% of the 265 Companies
in the Global Medical Devices industry.

( Industry Median: 2.68 vs. VAR: 2.12 )
Ranked among companies with meaningful Price/Graham Number only.
VAR' s Price/Graham Number Range Over the Past 10 Years
Min: 0.61  Med: 2.54 Max: 3.67
Current: 2.12
0.61
3.67
Earnings Yield (Greenblatt) (%) 8.10
VAR's Earnings Yield (Greenblatt) (%) is ranked higher than
86% of the 307 Companies
in the Global Medical Devices industry.

( Industry Median: 0.70 vs. VAR: 8.10 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
VAR' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 3.9  Med: 7.30 Max: 14.7
Current: 8.1
3.9
14.7
Forward Rate of Return (Yacktman) (%) 10.33
VAR's Forward Rate of Return (Yacktman) (%) is ranked higher than
71% of the 108 Companies
in the Global Medical Devices industry.

( Industry Median: 5.28 vs. VAR: 10.33 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
VAR' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 10  Med: 19.20 Max: 29.4
Current: 10.33
10
29.4

More Statistics

Revenue(Mil) $3118
EPS $ 4.10
Beta0.65
Short Percentage of Float8.32%
52-Week Range $71.07 - 96.67
Shares Outstanding(Mil)95.50

Analyst Estimate

Sep16 Sep17 Sep18
Revenue(Mil) 3,210 3,343 3,462
EPS($) 4.48 4.91 5.12
EPS without NRI($) 4.48 4.91 5.12

Latest Earnings Webcast

Call starts at Oct 28, 2015 05:00 PM EDT

» More Conference Calls

Business Description

Industry: Medical Devices » Medical Devices
Compare:WST, BAX, COV, TMO, COO » details
Traded in other countries:VNM.Germany,
Varian Medical Systems Inc is a Delaware corporation originally incorporated in the year 1948 as Varian Associates, Inc. The Company manufactures medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, proton therapy and brachytherapy. It is a supplier of x-ray imaging components for medical, scientific, and industrial applications and also supplies x-ray imaging products for cargo screening and industrial inspection. The Company has two reportable operating segments: Oncology Systems and X-ray Products. The Oncology Systems business segment designs, manufactures, sells and services hardware and software products for treating cancer with radiotherapy, stereotactic radiotherapy, stereotactic body radiotherapy, stereotactic radiosurgery and brachytherapy. Products include linear accelerators, brachytherapy afterloaders, treatment simulation and verification equipment and accessories; as well as information management, treatment planning and image processing software. Oncology Systems products enable radiation oncology departments in hospitals and clinics to perform conventional radiotherapy treatments and offer treatments such as fixed field intensity-modulated radiation therapy, image-guided radiation therapy, volumetric modulated arc therapy and stereotactic radiotherapy, as well as to treat patients using brachytherapy techniques, which involve temporarily implanting radioactive sources. The Company's Oncology Systems products are also used by neurosurgeons to perform stereotactic radiosurgery. Oncology Systems customers include university research and community hospitals, private and governmental institutions, healthcare agencies, physicians' offices and cancer care clinics. The X-ray Products business segment designs, manufactures, sells and services x-ray imaging components for use in a range of applications, including radiographic or fluoroscopic imaging, mammography, special procedures, computed tomography and industrial applications. The Company's x-ray imaging components are sold to large imaging system OEM customers that incorporate them into their medical diagnostic, dental, veterinary and industrial imaging systems. It sells x-ray tubes and flat panel digital image detectors for filmless x-ray imaging to small OEMs, independent service companies and directly to end-users for replacement purposes. The Company has three other businesses that are reported together under the Other category. The Company's imaging components business designs, manufactures, sells and services Linatron x-ray accelerators, imaging processing software and image detection products for security and inspection purposes, such as cargo screening at ports and borders and nondestructive examination in a variety of applications. The VPT business develops, designs, manufactures, sells and services products and systems for delivering proton therapy, a form of external beam radiotherapy using proton be
» More Articles for VAR

Headlines

Articles On GuruFocus.com
Wedgewood Partners Comments on Varian Medical Systems Jan 18 2016 
Wedgewood Partners 4th Quarter Client Letter: 'Back to Our Regularly Scheduled Stock Market' Jan 15 2016 
David Rolfe Trims Holdings in Alphabet, Visa in 3rd Quarter Nov 24 2015 
The Best Companies of the Medical Industry – September 2015 Sep 25 2015 
Wedgewood Partners 2nd Quarter 2015 Client Letter - Wedgewood On Sale Jul 20 2015 
Reversing a Declining Pattern in Earnings Per Share Feb 24 2015 
Edwards Lifesciences a Gold Standard in the Market Dec 16 2014 
No More a Simple Distributor Sep 07 2014 
Bearish Investor John Hussman's 5 Top New Stock Buys May 02 2014 
David Rolfe Comments on Varian Medical Systems Apr 18 2014 

More From Other Websites
VARIAN MEDICAL SYSTEMS INC Files SEC form 10-Q, Quarterly Report Feb 09 2016
Medical Appliances & Equipment Equities Ahead of Market -- ResMed, ZELTIQ Aesthetics, MiMedx Group,... Feb 03 2016
Varian Medical Systems, Inc. Earnings Analysis: Q1, 2016 By the Numbers Jan 29 2016
Varian (VAR) Beats Q1 Earnings and Revenue Estimates Jan 28 2016
Edited Transcript of VAR earnings conference call or presentation 27-Jan-16 10:00pm GMT Jan 28 2016
Varian Medical Systems Reports Results for First Quarter of Fiscal Year 2016 Jan 27 2016
VARIAN MEDICAL SYSTEMS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Jan 27 2016
Varian Medical Systems Reports Results for First Quarter of Fiscal Year 2016 Jan 27 2016
Q1 2016 Varian Medical Systems Inc Earnings Release - After Market Close Jan 27 2016
Varian Medical Systems Appoints Dr. Patrick Kupelian VP of Clinical Affairs Jan 26 2016
Varian Medical Systems Appoints Dr. Patrick Kupelian VP of Clinical Affairs Jan 26 2016
Varian (VAR) Q1 Earnings Preview: A Surprise in Store? Jan 25 2016
Varian Honored Among World's 100 Most Sustainable Corporations for Second Year Running Jan 21 2016
Varian Honored Among World's 100 Most Sustainable Corporations for Second Year Running Jan 21 2016
Varian Medical Update: Why Barrington Likes 'Clear Market Leader' Jan 12 2016
Varian ProBeam Proton Therapy System First to Receive Saudi FDA Authorization Jan 11 2016
Varian ProBeam Proton Therapy System First to Receive Saudi FDA Authorization Jan 11 2016
Varian Medical Systems 2015 Annual Report Now Available on Investor Web Site Jan 07 2016
Varian Medical Systems 2015 Annual Report Now Available on Investor Web Site Jan 07 2016
Varian Medical Systems, Inc. – Value Analysis (NYSE:VAR) : January 5, 2016 Jan 05 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK